Literature DB >> 7914090

Synthesis and properties of fluorescent beta-adrenoceptor ligands.

H Heithier1, D Hallmann, F Boege, H Reiländer, C Dees, K A Jaeggi, D Arndt-Jovin, T M Jovin, E J Helmreich.   

Abstract

We describe the synthesis of bordifluoropyrromethene (BODIPY), fluorescein, and related fluorescent derivatives of the beta-adrenergic ligand CGP 12177. With these probes we screened insect (Sf9) cells stably transformed with the human beta 2-adrenoceptor gene and expressing (2-3.5) x 10(5) human beta 2-adrenoceptors per cell. Among these derivatives only BODIPY-CGP gave a receptor-specific signal sufficiently strong for measuring the on- and off-rate constants and the equilibrium dissociation constant of beta-adrenoceptor-specific binding by spectrofluorometry or photon counting. Similar KD values for BODIPY-CGP binding were obtained by kinetic measurements (approx. 250 pM) and under equilibrium conditions (400 +/- 180 pM), and these were in the same range as those obtained with [3H]CGP 12177 (200 +/- 32 pM). The cell-bound fluorescence could be quenched specifically with nonfluorescent CGP 12177 to near background levels. The disposition of the beta 2-adrenoceptors in BODIPY-CGP-stained Sf9 cells was mainly restricted to the cell surface at 4 and 30 degrees C. Hence, beta-adrenoceptor-expressing cells can be stained specifically with BODIPY-CGP, and beta-adrenoceptors on a single cell can be assessed by photon counting under the fluorescence microscope. Cells can also be scanned by fluorescence-activated flow cytometry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914090     DOI: 10.1021/bi00197a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Do fluorescent drugs show you more than you wanted to know?

Authors:  J C McGrath; C J Daly
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 2.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

Review 3.  Fluorescent ligands: Bringing light to emerging GPCR paradigms.

Authors:  Mark Soave; Stephen J Briddon; Stephen J Hill; Leigh A Stoddart
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

4.  Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

5.  Ways and means of coping with uncertainties of the relationship of the genetic blue print to protein structure and function in the cell.

Authors:  Ernst Jm Helmreich
Journal:  Cell Commun Signal       Date:  2010-09-17       Impact factor: 5.712

6.  Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.

Authors:  Jillian G Baker; Luke A Adams; Karolina Salchow; Shailesh N Mistry; Richard J Middleton; Stephen J Hill; Barrie Kellam
Journal:  J Med Chem       Date:  2011-09-16       Impact factor: 7.446

7.  Analysis of fluorescently labeled substance P analogs: binding, imaging and receptor activation.

Authors:  Vicki J Bennett; Mark A Simmons
Journal:  BMC Chem Biol       Date:  2001

8.  High-Affinity Functional Fluorescent Ligands for Human β-Adrenoceptors.

Authors:  Gyuzel Y Mitronova; Gražvydas Lukinavičius; Alexey N Butkevich; Tobias Kohl; Vladimir N Belov; Stephan E Lehnart; Stefan W Hell
Journal:  Sci Rep       Date:  2017-09-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.